Back to Newslist October 26 | 2016

After a successful feasibility study where Vectron's proprietary expression vector technology platform was used to develop a robust production process for the Candida antarctica CalB enzyme, Vectron and EnginZyme have today signed a license agreement. EnginZyme AB is a Stockholm-based biocatalysis company and has now received the commercial rights to use Vectron's expression vector technology platform for manufacture of CalB for biocatalysis applications. This agreement includes the right to combine the CalB enzyme with EnginZyme's proprietary EziG immobilization matrix.